After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

Usually described as a splitting or multiple personality disorder, the concept of schizophrenia is not entirely but rather a ...

There are as yet no effective drugs for negative symptoms like social withdrawal and lack of motivation. Read more at ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030.

At the Institute of Mental Health (IMH), almost 60 per cent to 70 per cent of patients with schizophrenia make a good ...

AVXL stock soars 95% in three months on positive updates from the development programs of its two clinical candidates, blarcamesine and ANAVEX 3-71.

Xanomeline and trospium chloride (KarXT), a novel M1/M4 muscarinic receptor agonist, significantly improves cognitive ...

Boehringer Ingelheim announced that its schizophrenia drug, iclepertin, did not achieve statistically significant ...

Peptide antigen-associated IgG levels were significantly lower in drug-naïve patients with first episode psychosis compared to control individuals.

As per the Brain and Behavior Research Foundation, it combines two compounds called xanomeline and trospium chloride. This is ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.